PGxAI Launches Sirius, an AI‑Powered Pharmacogenetics Model, to Advance Ultra‑Precision Medicine

PALO ALTO, Calif., Dec 19, 2024 - PGxAI, a leader in AI‑driven pharmacogenetics, launches Sirius, a breakthrough AI model that personalizes drug selection, dosage adjustment, and drug‑drug interaction management based on an individual’s genome. Sirius helps hospital systems, diagnostic labs, and contract research organizations enhance clinical efficacy and minimize adverse effects of prescribed therapies.

“Sirius marks a pivotal advancement in pharmacogenetics, delivering a scale of insight and precision previously unattainable in our field without advanced AI,” said Dr. Mike Zack, PGxAI co‑founder and CEO. “While other existing solutions allowed for insights on up to 300 drugs and 20 genes, Sirius covers 730 drugs and up to 40 genes critical to drug metabolism.”

The first in a series of pharmacogenetics models, Sirius is pioneering a new approach in personalized medicine as PGxAI works toward expanding its platform to cover all known and potential therapeutic substances by 2030.

“Adverse drug reactions are one of the top three causes of death in the U.S.,” said Allan Gobbs, PGxAI Chairman and co‑founder. “One of the greatest threats to health today is the tendency to overlook genetics in treatment—an oversight where PGxAI could save lives. Studies reveal that pharmacogenetics can prevent nearly 30% of these adverse reactions. At PGxAI, we’re committed to making this level of care the new standard in medicine.”

PGxAI’s strategic partnerships with technology leaders, including Nvidia, Microsoft, Google, Meta, AWS, and InterSystems, underpin this development. Through InterSystems’ HealthShare platform, PGxAI connects seamlessly with diverse health systems, supporting data exchange and robust information management.

“Precision medicine is quickly becoming integral to EHR systems with genomics adding to a more complete picture of patient health,” said Don Woodlock, Head of Global Healthcare Solutions for InterSystems. “As a partner in the InterSystems innovation ecosystem, PGxAI demonstrates how this wealth of information, combined with real‑world evidence, can be processed and interpreted to deliver highly tailored and effective therapeutic guidance.”

The platform's efficacy is further amplified by its access to an ever‑growing repository of clinical data. Starting with a few thousand health outcomes in the initial phase, PGxAI aims to integrate data from over 1 billion health outcomes by 2030. This expansive dataset enables PGxAI to refine its insights continually, ensuring that therapeutic recommendations are both precise and deeply informed by real‑world evidence. As the platform scales, PGxAI’s robust data foundation empowers healthcare providers to deliver increasingly personalized and effective treatments.

A series of next‑generation models following Sirius will leverage advanced technologies like GenAI, Federated Learning, and Real‑World Evidence. The initial results from the Sirius model were presented at the IEEE COMPSAC 2024 scientific conference in Osaka earlier this year. By 2025, PGxAI plans to expand its substance coverage to 1,700 drugs. By 2026, the company aims to incorporate Generative AI across its models, enhancing the precision and depth of its therapeutic recommendations.

PGxAI is backed by ATEM Capital, a New York‑based venture capital firm specializing in Life Sciences. Focused on transformative technologies in bioplatforms, molecular diagnostics, and AI‑driven digital health, ATEM Capital supports innovations with the potential to meet critical clinical needs and advance precision medicine.

About InterSystems

Established in 1978, InterSystems is the leading provider of next‑generation solutions for enterprise digital transformations in the healthcare, finance, manufacturing, and supply chain sectors. Its cloud‑first data platforms solve interoperability, speed, and scalability problems for large organizations around the globe. InterSystems is committed to excellence through its award‑winning, 24×7 support for customers and partners in more than 80 countries. Privately held and headquartered in Cambridge, Massachusetts, InterSystems has 39 offices in 28 countries worldwide. For more information, please visit InterSystems.com.

About PGxAI

Launched in 2023, Palo Alto‑based PGxAI stands at the forefront of pharmacogenetics, leveraging AI and real‑world data to drive innovation in precision medicine. The platform employs proprietary algorithms to personalize drug selection, dosage, and interaction management. PGxAI is led by a team of scientists, AI experts and serial entrepreneurs, including CEO and сo‑founder Dr. Mike Zack, MD, PhD, a UCSF pharmacogenomics expert, and executive chairman and co‑founder Allan Gobbs, a seasoned Life Sciences VC. The advisory board includes Dr. Russ Altman of Stanford University and executives from Thermo Fisher, GE Healthcare, and Tempus AI. Backed by New York‑based ATEM Capital and in strategic partnership with InterSystems, PGxAI seeks to address the critical need for tailored, effective therapies in healthcare, and set new standards for precision medicine.